Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Raw Materials (2016 - 2025)

Historic Raw Materials for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Q3 2025 value amounting to $105.8 million.

  • Amphastar Pharmaceuticals' Raw Materials rose 7470.43% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 7470.43%. This contributed to the annual value of $81.5 million for FY2024, which is 6275.51% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Raw Materials is $105.8 million, which was up 7470.43% from $106.5 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Raw Materials' 5-year high stood at $106.5 million during Q2 2025, with a 5-year trough of $40.4 million in Q1 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Raw Materials value was $47.9 million (recorded in 2023), while the average stood at $58.8 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Raw Materials tumbled by 2063.19% in 2021 and then skyrocketed by 10083.64% in 2025.
  • Amphastar Pharmaceuticals' Raw Materials (Quarter) stood at $41.9 million in 2021, then increased by 13.75% to $47.6 million in 2022, then increased by 5.2% to $50.1 million in 2023, then soared by 62.76% to $81.5 million in 2024, then grew by 29.75% to $105.8 million in 2025.
  • Its Raw Materials was $105.8 million in Q3 2025, compared to $106.5 million in Q2 2025 and $103.3 million in Q1 2025.